KindredBio is focused on bringing breakthrough human products and innovative new technologies to veterinary medicine to address unmet clinical needs and provide benefits to animal companions. We identify drugs, biologics, and targets that have been validated in humans and develop animal versions to treat and cure pets. We seek to leverage the investments that have been made in human pharmaceutical R&D to develop therapies for pets with lower risk, lower cost, and shorter time-to-market, compared to human drug development. We believe KindredBio can deliver superior returns to investors because while the market sizes for pet drugs are about 10-fold smaller compared to human market sizes, the cost of development is 100-fold less.
Source
